Proactive Infliximab Monitoring Improves the Rates of Transmural Remission in Crohn’s Disease: A Propensity Score–Matched Analysis

Author:

Fernandes Samuel Raimundo123ORCID,Bernardo Sónia13,Saraiva Sofia13,Rita Gonçalves Ana13,Moura Santos Paula123,Valente Ana1,Araújo Correia Luís123,Cortez-Pinto Helena12ORCID,Magro Fernando43ORCID

Affiliation:

1. Serviço de Gastrenterologia e Hepatologia, Hospital Santa Maria, Centro Hospitalar Universitário Lisboa Norte EPE , Lisbon , Portugal

2. Clínica Universitária de Gastrenterologia da Faculdade de Medicina de Lisboa , Lisbon , Portugal

3. Portuguese Group of Studies in Inflammatory Bowel Disease, Gedii , Porto , Portugal

4. CINTESIS@RISE, Faculty of Medicine, University of Porto , Porto , Portugal

Abstract

Abstract Background Few patients can reach transmural remission in Crohn’s disease (CD) with currently available therapies. Proactive optimization of infliximab (IFX) based on trough levels may potentially improve these results. Methods Retrospective cohort study including consecutive CD patients starting treatment with IFX. Rates of transmural remission were compared between patients with and without therapeutic drug monitoring (target level: 5-7 µg/mL). A propensity score–matched analysis was performed to adjust for potential confounders. Results A total of 195 CD patients were included, 57.9% receiving proactive therapeutic drug monitoring. The rates of transmural remission were higher in patients under proactive therapeutic drug monitoring (37.2% vs 18.3%; P = .004) with similar results in the propensity score–matched analysis (34.2% vs 17.1%; P = .025). In multivariate analysis, proactive therapeutic drug monitoring was independently associated with transmural remission (odds ratio, 2.95; 95% confidence interval, 1.44-6.06; P = .003). Conclusions Proactive optimization of IFX based on trough levels increases the rates of transmural remission in CD.

Publisher

Oxford University Press (OUP)

Subject

Gastroenterology,Immunology and Allergy

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3